Literature DB >> 26220972

Mutation p.L799R in the LDLR, which affects the transmembrane domain of the LDLR, prevents membrane insertion and causes secretion of the mutant LDLR.

Thea Bismo Strøm1, Jon K Laerdahl2, Trond P Leren3.   

Abstract

Mutations in the low-density lipoprotein receptor (LDLR) gene cause familial hypercholesterolemia (FH). The mechanism by which mutations in the LDLR affecting the transmembrane domain of the receptor cause FH has not been thoroughly investigated. In this study, we have selected 12 naturally occurring mutations affecting the transmembrane domain and studied their effect on the LDLR. The main strategy has been to transiently transfect HepG2 cells with mutant LDLR plasmids and to study the mutant LDLRs in cell lysates and in media by western blot analysis. The most striking finding was that mutation p.L799R led to secretion of the entire 160 kDa mature L799R-LDLR. Residue 799Leu is in the middle of the 22-residue transmembrane domain, and introduction of a basic residue in the hydrophobic core of the transmembrane domain could prevent L799R-LDLR from being correctly recognized and integrated in the membrane by the Sec61 translocon complex. This would then lead to translocation of the entire L799R-LDLR into the lumen of the endoplasmic reticulum. Mutation p.L799R should be considered a member of a separate class of FH-causing mutations that affects the insertion of the LDLR in the cell membrane.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26220972     DOI: 10.1093/hmg/ddv304

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  5 in total

Review 1.  Endoplasmic reticulum quality control in lipoprotein metabolism.

Authors:  Cari M Koerner; Benjamin S Roberts; Saskia B Neher
Journal:  Mol Cell Endocrinol       Date:  2019-08-20       Impact factor: 4.102

2.  The UCL low-density lipoprotein receptor gene variant database: pathogenicity update.

Authors:  Sarah Leigh; Marta Futema; Ros Whittall; Alison Taylor-Beadling; Maggie Williams; Johan T den Dunnen; Steve E Humphries
Journal:  J Med Genet       Date:  2016-11-07       Impact factor: 6.318

Review 3.  Validation of LDLr Activity as a Tool to Improve Genetic Diagnosis of Familial Hypercholesterolemia: A Retrospective on Functional Characterization of LDLr Variants.

Authors:  Asier Benito-Vicente; Kepa B Uribe; Shifa Jebari; Unai Galicia-Garcia; Helena Ostolaza; Cesar Martin
Journal:  Int J Mol Sci       Date:  2018-06-05       Impact factor: 5.923

4.  Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity.

Authors:  Poulabi Banerjee; Kuo-Chen Chan; Michel Tarabocchia; Asier Benito-Vicente; Ana C Alves; Kepa B Uribe; Mafalda Bourbon; Paul J Skiba; Robert Pordy; Daniel A Gipe; Daniel Gaudet; Cesar Martin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-10-03       Impact factor: 8.311

Review 5.  Proteostasis Regulation in the Endoplasmic Reticulum: An Emerging Theme in the Molecular Pathology and Therapeutic Management of Familial Hypercholesterolemia.

Authors:  Deepu Oommen; Praseetha Kizhakkedath; Aseel A Jawabri; Divya Saro Varghese; Bassam R Ali
Journal:  Front Genet       Date:  2020-09-23       Impact factor: 4.599

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.